Molecular pathways: Protein methyltransferases in cancer

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6344-6350

  Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EPZ 5676; EPZ 6438; LYSINE; METHYLTRANSFERASE INHIBITOR; PROTEIN METHYLTRANSFERASE; PROTEIN METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GENETICS; CELL PROLIFERATION; CHROMATIN; CHROMOSOME TRANSLOCATION; DRUG POTENCY; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; NEOPLASM; NONHUMAN; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN METHYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84890284556     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0223     Document Type: Article

References (45)

1. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005;44:7342-72.
2. Allis CD, Jenuwein T, Reinberg D, Caparros M-L. Epigenetics. New York: Cold Spring Harbor Press; 2007.
3. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-32.
4. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
5. Copeland RA, Moyer MP, Richon VM. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 2013;32:939-46.
6. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011;78:199-210.
7. Webb KJ, Lipson RS, Al-Hadid Q, Whitelegge JP, Clarke SG. Identi-.cation of protein N-terminal methyltransferases in yeast and humans. Biochemistry 2010;49:5225-35.
8. Copeland RA. Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discov Today Ther Strateg 2012;9:e83-e90.
9. Pollock RM, Daigle SR, Therkelsen CA, Basavapathruni A, Jin L, Allain CJ, et al. Preclinical characterization of a potent, selective inhibitor of the protein methyltransferase DOT1L for use in the treatment of MLLrearranged leukemia [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec. 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 2379.
10. Keilhack H, Yokoi A, Knutson SK, Wigle T, Warholic N, Kawano S, et al. Preclinical characterization of E7438, a potent, selective inhibitor of protein methyltransferase EZH2 with robust antitumor activity against EZH2 mutated non-Hodgkin lymphoma xenografts in mice [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec. 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 3712.
11. Cheng X, Collins RE, Zhang X. Structural and sequence motifs of protein (Histone) methylation enzymes. Annu Rev Biophys Biomol Struct 2005;34:267-94.
12. Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. 2nd ed. New York: Wiley; 2013.
13. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
14. Lee JS, Smith E, Shilatifard A. The language of histone crosstalk. Cell 2010;142:682-5.
15. Martinez-Garcia E, Popovic R, Min D-J, Sweet S M M, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4;14) multiple myeloma cells. Blood 2011;117:211-20.
16. Decarlo D, Hadden MK. Oncoepigenomics: making histone lysine methylation count. Eur J Med Chem 2012;56:179-94.
17. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012;7:283-301.
18. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. MLL targets SET domain methyltransferase activity to hox gene promoters. Mol Cell 2002;10:1107-17.
19. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002;10:1119-28.
20. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 2004;10:500-7.
21. Krivtsov AV, Armstrong SA. MLLtranslocations, histone modifications, and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33.
22. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Cofield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-78.
23. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007;16:92-106.
24. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007;110:4445-54.
25. Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem 2006;281:18059-68.
26. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20:66-78.
27. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 2005;65:11367-74.
28. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65.
29. Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, et al. Conformational adaption drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012;80:971-80.
30. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012;3:1288.
31. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008;111:3145-54.
32. Li B, Jackson J, Simon MD, Fleharty B, Gogol M, Seidel C, et al. Histone H3 lysine 36 dimethylation (H3K36me2) is suficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription. J Biol Chem 2009;284:7970-6.
33. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t (4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34.
34. Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t (4;14) (p16;q32)-positive multiple myeloma patients. Blood 2005;105:4060-9.
35. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t (4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520-9.
36. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
37. Bodor C, Vera G, Kohlmann A, Tan K, Okosun J, Popov N, et al. High incidence of EZH2 mutations with variable mutation load in follicular lymphoma and its consequences for EZH2 targeted therapy[abstract]. In Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec. 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 545.
38. Sneeringer C, Scott MP, Kuntz K, Knutson SK, Pollock RM, Richon V, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010;107:20980-5.
39. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-8.
40. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012;109:2989-94.
41. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
42. Ginn KF, Gajjar A. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2012;2:114.
43. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho Y-J, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010;18:316-28.
44. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013;110:7922-7.
45. Daigle SR, Ohava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin A, et al. A DOT1L inhibitor blocks MLL-fusion leukemia. Blood 2013;122:1017-25.